14-05-2025
Hy2Care® secures €4.5 million in funding to prepare for U.S. clinical trial and commercial expansion
Hy2Care® has successfully raised €4.5 million in new funding to complete critical preparations for its upcoming clinical trial in the United States. The company recently received FDA Investigational Device Exemption (IDE) approval, allowing it to start clinical evaluation of its CartRevive® hydrogel implant for cartilage repair. The funding will also support strategic steps toward commercial rollout in Europe and other key global markets. This funding round reflects growing confidence in Hy2Care’s CartRevive hydrogel platform and its potential to set a new standard in cartilage repair — offering surgeons and patients a simple, effective, and minimally invasive alternative to current treatments.
Half of the funding comes from the European Innovation Council (EIC) Fund investment awarded to Hy2Care in 2022 as part of the EIC Accelerator. The remainder was raised from Hy2Care’s existing shareholders, led by Brightlands Venture Partners, with participation from new investors including LIOF, the regional development agency for Limburg.
“This round gives us the momentum we need to take the next big step.” said Leo Smit, CEO of Hy2Care. “We’re entering a transformative phase — launching a U.S. clinical trial while laying the foundation for commercialization in EMEA. We are incredibly proud of the support from our investors, both existing and new.”
Download press release (pdf)
